RNAi Therapeutics and Technology Market Size is valued at USD 1.59 Bn in 2023 and is predicted to reach USD 5.36 Bn by the year 2031 at an 16.6% CAGR during the forecast period for 2024-2031.
RNA interference (RNAi) therapeutics and technology represent a cutting-edge approach to disease treatment, utilizing the cell's natural regulatory mechanism to silence specific genes implicated in various disorders. At the core of RNAi technology lie small interfering RNA (siRNA) and microRNA (miRNA) molecules, which target and neutralize disease-causing genes with remarkable precision when introduced into the body. Through this mechanism, RNAi therapeutics offer a tailored and potent means of addressing a broad spectrum of medical conditions.
The applications of RNAi therapeutics span various diseases, ranging from genetic disorders and oncological malignancies to viral infections and neurodegenerative conditions. RNAi therapies hold promise in preventing diseases at their molecular roots by selectively silencing target genes. Additionally, RNAi technology has demonstrated efficacy in addressing cardiovascular diseases, kidney ailments, respiratory disorders, and various infectious diseases, marking a transformative shift in the landscape of medical intervention.
The increasing investments in RNAi therapy development are driving the RNAi therapeutics market forward. Driven by the acknowledgement of RNAi technology's potency in precision medicine and its expansive therapeutic potential, biotech firms and pharmaceutical companies are eagerly engaged in research and development activities, injecting substantial funds into advancing RNAi-based treatments.
Competitive Landscape
Some of the Key Players in RNAi Therapeutics and Technology Market:
- Alnylam Pharmaceuticals, Inc.
- Novartis
- Sylentis, S.A.
- Dicerna Pharmaceuticals (Novo Nordisk company)
- Arbutus Biopharma
- Sanofi
- Arcturus Therapeutics, Inc.
- Lilly
- Hoffmann-La Roche Ltd
- ARIZ Precision Medicine
- Arrowhead Pharmaceuticals, Inc.
- Sirnaomics
- Gradalis Inc.,
- Silence Therapeutics
- Merck & Co. Inc. (Sigma Aldrich)
- QIAGEN
- Phio Pharmaceuticals
Market Segmentation:
The RNAi therapeutics and technology market is segmented based on type, application, route of administration and end-user. By type, the market is segmented into small interfering RNA (siRNA), MicroRNA (miRNA); by application, market is categorized into genetic disorders, oncology, neurodegenerative disorders, infectious diseases, renal diseases, and others. Route of administration segment is categorized into intradermal injections, pulmonary delivery, and intravenous injections. The market is segmented into diagnostic laboratories, research and academic laboratories, and hospitals by end-user.
siRNA (small interfering RNA) is Expected to Drive the RNAi Therapeutics and Technology Market
The increasing preference for siRNA (small interfering RNA) in drug development stems from its exceptional specificity in targeting disease-causing genes, potent gene silencing activity, and advancements in delivery technologies, which collectively enhance therapeutic efficacy. SiRNAs' ability to precisely silence single genes minimizes off-target effects, making them attractive for various diseases. Moreover, the rise in research collaborations and partnerships has accelerated siRNA-based therapy development, aided by successful clinical outcomes and regulatory approvals. This collaborative momentum, coupled with ongoing advancements in the field, solidifies siRNA's position as the leading segment in the RNAi market for drug development, promising novel and effective treatments for diverse medical conditions.
The Oncology Segment is Growing at the Highest Rate in the RNAi Therapeutics and Technology Market.
The oncology segment is emerging in the RNAi therapeutics market, driven by multiple factors. Firstly, the high prevalence of cancer globally fuels the demand for effective treatments like RNAi therapeutics, with the American Cancer Society projecting around 1.9 million new cases and 609,360 fatalities in the United States alone for 2022. Furthermore, RNAi therapeutics demonstrate significant promise in cancer treatment, precisely targeting disease-causing genes and offering a tailored approach to modulating gene expression within tumour cells or tissues. Lastly, ongoing research and development efforts in oncology-specific RNAi therapeutics underscore a robust landscape of innovation and collaboration among companies, further propelling advancements in treating tumors and related conditions.
Regionally, North America Led the RNAi Therapeutics and Technology Market.
North America, particularly the United States, leads the RNAi therapeutics market due to its robust biotechnology sector, encompassing top-notch universities and research institutions that drive innovation in RNAi technology. Supported by favorable regulatory agencies like the FDA, the region fosters the approval and commercialization of RNAi-based therapies. High healthcare expenditure levels and well-established healthcare systems further bolster the adoption of innovative treatments. Additionally, key players and collaborative efforts among biopharmaceutical companies and academic institutions actively propel the development and commercialization of RNAi-based treatments, solidifying North America's dominance in the global RNAi therapeutics market.
RNAi Therapeutics and Technology Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 1.59 Bn |
|
Revenue Forecast In 2031 |
USD 5.36 Bn |
|
Growth Rate CAGR |
CAGR of 16.6 % from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Type, By Application, By Route of Administration, By End-User |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; Southeast Asia |
|
Competitive Landscape |
Alnylam Pharmaceuticals, Inc., Novartis, Sylentis, S.A., Dicerna Pharmaceuticals (Novo Nordisk company), Arbutus Biopharma, Sanofi, Arcturus Therapeutics, Inc., Lilly, F. Hoffmann-La Roche Ltd, ARIZ Precision Medicine, Arrowhead Pharmaceuticals, Inc., Sirnaomics, Gradalis Inc., Silence Therapeutics, Merck & Co. Inc. (Sigma Aldrich), QIAGEN, Phio Pharmaceuticals |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Geographic competitive landscape. |
|
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
